open
Logo
Choose your language
Nederlands
Nederlands

Oncologie

Welcome to Janssen Medical Cloud — Oncology

Janssen Medical Cloud Oncology is a platform that provides you as a healthcare professional with relevant and useful information in the field of uro-oncology, and more specifically with regard to prostate cancer.

This professional platform gives you easy access to our online and offline medical education programs, which include the most recent updates from the major conferences within your field (ASCO, ASCO-GU, ESMO, EAU, APCCC).

In addition, you can access our clinical trials and the Janssen oncology portfolio from this resource with ease — including all supporting scientific studies and useful materials for your patients.

Medical_Team_2.jpg
Ontdek ons portfolio

Lees meer over onze producten m.b.t. de behandeling van prostaatkanker.

General-blauw_achtergrond.jpg
Bezoek ons medical education platform

Oncology Medical Education (OME) biedt scholing en is een platform om inzichten op het gebied van oncologie uit te wisselen.

Raadpleeg onze kalender

Janssen volgt de medische actualiteit op de voet en stelt voor u een handige kalender samen met de belangrijkste evenementen in uw vakgebied.

Bekijk onze ondersteunende materialen

Download of bestel materialen om de behandeling van uw patiënten te ondersteunen.

News

European market authorization for Erleada (Apalutamide)

On January 27, 2020, the European Commission (EMA) announced approval of ERLEADA for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with ADT. Until now, ERLEADA was only registered for adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of metastatic disease.

Erleada (Apalutamide) now reimbursed in Luxembourg

From July 2020, ERLEADA® will be reimbursed in Luxembourg (national no. 0885824) in adult men for the treatment of:

  • non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of developing metastatic disease
  • metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)
Erleada (Apalutamide) now reimbursed in Belgium

From September 2021, ERLEADA will be reimbursed in Belgium in adult men for the treatment of:

  • non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of developing metastatic disease in combination with androgen deprivation therapy (ADT)
  • metastatic hormone-sensitive prostate cancer (mHSPC) in combination with ADT

Resources

Online bibliotheek

In de online bibliotheek kunt u >800 oncologieboeken digitaal inkijken.

Behandelingsrichtlijnen

Raadpleeg de selectie van richtlijnen met aanbevelingen rond de behandeling van prostaatkanker.

Contacteer ons

Hebt u een vraag voor ons of niet gevonden wat u zoekt? Neem contact op, wij helpen u graag verder.

Ontdek onze producten

Ontdek hier het Janssen portfolio en de bijbehorende SmPC's.

Bekijk 3D-ziektebeelden

Ontdek interactieve 3D-animaties van de menselijke anatomie en verschillende ziektebeelden.

*PSA: Prostate-Specific Antigen

CP-183545 - October 2020